Does AMIVANTAMAB Cause Interstitial lung disease? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Interstitial lung disease have been filed in association with AMIVANTAMAB (Rybrevant). This represents 2.1% of all adverse event reports for AMIVANTAMAB.
16
Reports of Interstitial lung disease with AMIVANTAMAB
2.1%
of all AMIVANTAMAB reports
7
Deaths
4
Hospitalizations
How Dangerous Is Interstitial lung disease From AMIVANTAMAB?
Of the 16 reports, 7 (43.8%) resulted in death, 4 (25.0%) required hospitalization, and 7 (43.8%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for AMIVANTAMAB.
What Other Side Effects Does AMIVANTAMAB Cause?
Infusion related reaction (62)
Rash (61)
Pulmonary embolism (41)
Dermatitis acneiform (34)
Thrombocytopenia (33)
Paronychia (29)
Diarrhoea (25)
Pneumonitis (24)
Dyspnoea (23)
Nausea (23)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which AMIVANTAMAB Alternatives Have Lower Interstitial lung disease Risk?
AMIVANTAMAB vs AMIVANTAMAB-VMJW
AMIVANTAMAB vs AMLODIPINE
AMIVANTAMAB vs AMLODIPINE BESILATE
AMIVANTAMAB vs AMLODIPINE\ATORVASTATIN
AMIVANTAMAB vs AMLODIPINE\BENAZEPRIL